Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. [electronic resource]
Producer: 20161213ISSN:- 2047-9980
- Adrenergic beta-Antagonists -- adverse effects
- Adult
- Aged
- Angiotensin II Type 1 Receptor Blockers -- therapeutic use
- Angiotensin-Converting Enzyme Inhibitors -- therapeutic use
- Bisoprolol -- adverse effects
- Carbazoles -- adverse effects
- Carvedilol
- Chi-Square Distribution
- Databases, Factual
- Delayed-Action Preparations
- Drug Compounding
- Female
- Heart Failure -- diagnosis
- Humans
- Kaplan-Meier Estimate
- Kidney Failure, Chronic -- diagnosis
- Male
- Metoprolol -- adverse effects
- Middle Aged
- Multivariate Analysis
- Propanolamines -- adverse effects
- Propensity Score
- Proportional Hazards Models
- Renal Dialysis -- adverse effects
- Retrospective Studies
- Risk Factors
- Taiwan
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.